^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AB-1015
i
Other names: AB-1015
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ArsenalBio
Drug class:
Mesothelin-targeted CAR-T immunotherapy, ALPP-targeted CAR-T immunotherapy, ALPPL2-targeted CAR-T immunotherapy
Related drugs:
3ms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Arsenal Biosciences, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
BRCA2 mutation • BRCA1 mutation
|
cyclophosphamide • AB-1015
8ms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Arsenal Biosciences, Inc. | Trial primary completion date: Mar 2024 --> Dec 2024
Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
BRCA2 mutation • BRCA1 mutation
|
cyclophosphamide • AB-1015
1year
Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer (SITC 2023)
Conclusions AB-1015 is specific for ALPG/P+MSLN+, demonstrates superior potency compared with logic gated T cells alone, and is resistant to ovarian TME suppression in preclinical studies. Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755).
Preclinical
|
MSLN (Mesothelin) • FASLG (Fas ligand) • ALPG (Alkaline Phosphatase) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2)
|
MSLN expression • ALPG expression
|
AB-1015
over1year
Preclinical Development of AB-1015, an Integrated Circuit T Cell Therapy Containing an ALPG/MSLN Logic Gate and FAS/PTPN2 shRNA-miR, for the Treatment of Ovarian Cancer (ASGCT 2023)
As a result, AB-1015 is capable of completely clearing these otherwise difficult-to-treat tumors in this model.In summary, AB-1015 is specific for ALPG/P+MSLN+, demonstrates superior potency, expansion, and persistence compared with logic gated T cells alone, and is resistant to ovarian TME suppression in preclinical studies. Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755) to assess the safety, pharmacokinetics, immunogenicity, and efficacy for patients with platinum-resistant ovarian cancer.
Preclinical
|
MSLN (Mesothelin) • FASLG (Fas ligand) • ALPG (Alkaline Phosphatase) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2)
|
MSLN expression • ALPG expression
|
AB-1015
2years
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Arsenal Biosciences, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated) • ALPG (Alkaline Phosphatase)
|
BRCA2 mutation • BRCA1 mutation • ALPG expression
|
cyclophosphamide • AB-1015
2years
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Arsenal Biosciences, LLC
New P1 trial
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated) • ALPG (Alkaline Phosphatase)
|
BRCA2 mutation • BRCA1 mutation • ALPG expression
|
cyclophosphamide • AB-1015
Share via
